Mirdametinib in Histiocytic Disorders — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Mirdametinib in Histiocytic Disorders — Stella

Home/Langerhans Cell Histiocytosis (LCH)/

View on ClinicalTrials.gov

Recruiting

Back to Langerhans Cell Histiocytosis (LCH) trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Key details

Phase

Safety & dosing

Sponsor

Children's Hospital Medical Center, Cincinnati

Enrollment target

~40 participants

Started

February 2024

Primary completion

March 2030

Age range

2 Years and older

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.